BTIG analyst David Larsen lowered the firm’s price target on Doximity (DOCS) to $50 from $80 and keeps a Buy rating on the shares after its Q3 results and outlook. The company highlighted uncertainty around Most Favored Nation pricing, across the bio-pharma market leading up to the end of 2025 and the subsequent impact on the selling season as the reason for the lighter guide, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $55 from $75 at Needham
- Doximity price target lowered to $40 from $70 at Piper Sandler
- Doximity price target lowered to $45 from $55 at Wells Fargo
- Doximity: Rebounding Pharma Momentum, Emerging AI Upside, and Attractive Valuation Support Renewed Growth Buy Thesis
- Doximity upgraded to Neutral from Underweight at JPMorgan